Flynn Zito Capital Management LLC Increases Stake in Eli Lilly and Company $LLY

Key Points

• Flynn Zito Capital Management more than doubled its Eli Lilly position in the fourth quarter, increasing its stake by 117.3% to 2,143 shares valued at about $2.3 million.
• Institutional ownership remains very high, with hedge funds and other institutions holding 82.53% of Eli Lilly’s stock, and several other firms also recently increased their positions.
• Wall Street remains bullish on LLY, with multiple analysts raising price targets and the stock carrying a consensus Moderate Buy rating with an average target price of $1,218.33.

Flynn Zito Capital Management LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 117.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,143 shares of the company's stock after purchasing an additional 1,157 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of Flynn Zito Capital Management LLC's investment portfolio, making the stock its 23rd largest holding. Flynn Zito Capital Management LLC's holdings in Eli Lilly and Company were worth $2,304,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Cidel Asset Management Inc. grew its stake in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Spire Wealth Management grew its stake in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after acquiring an additional 592 shares during the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after acquiring an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after acquiring an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its stake in shares of Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock worth $126,022,000 after acquiring an additional 5,595 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Rothschild & Co Redburn boosted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a report on Thursday, January 29th. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,218.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Eli Lilly and Company Trading Down 1.6%

Eli Lilly and Company stock opened at $988.76 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a market capitalization of $931.15 billion, a price-to-earnings ratio of 35.12, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. The stock has a 50-day moving average price of $940.00 and a 200 day moving average price of $999.39.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. The company's revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.